Vitro Diagnostics Launches New Stem Cell Products for Clinical Use & Presents Webinar with HemoGenix Inc.

GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of several new stem cell products including those with application to clinical studies. The new products were presented to the scientific community in a webinar jointly produced with our strategic partner, HemoGenix®, Inc. entitled “Mesenchymal Stem/Stromal Cells: Advances in Assays and Growth/Differentiation Media.” Vitro’s catalog now consists of adult stem cells, their fluorescent derivatives, and an expanded menu of tools for cellular reprogramming of adult cells to the functional equivalent of embryonic stem cells. Vitro now offers several additional formulations of its highly competitive MSCGro™ stem cell media product line together with advanced analytical tools, jointly manufactured with HemoGenix®, Inc., for the determination of stem cell quality, potency and response to toxic agents.